Francisco J. Hernandez

Oncology

100 College Pkwy Ste 290
Buffalo, NY 14221

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 27, 2026

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Journal: Blood advances

Published: December 08, 2025

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Journal: Blood advances

Published: December 08, 2025

Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience.

Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience.

Journal: Leukemia & lymphoma

Published: December 05, 2025

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 09, 2025

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 07, 2025

Risk of musculoskeletal disorders associated with Bruton's tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysis.

Risk of musculoskeletal disorders associated with Bruton's tyrosine kinase inhibitors: a disproportionality analysis of FAERS database and meta-analysis.

Journal: Expert opinion on drug safety

Published: June 16, 2025

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

Journal: Leukemia & lymphoma

Published: May 21, 2025

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Journal: Blood

Published: March 06, 2025

Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.

Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: September 27, 2024

Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation.

Small-molecule MMRi36 induces apoptosis in p53-mutant lymphomas by targeting MDM2/MDM4/XIAP for degradation.

Journal: Frontiers in oncology

Published: July 09, 2024

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.

Journal: Blood advances

Published: May 22, 2024

Showing 1-12 of 98

Last Updated: 09/26/2026